Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma

Background: Wixela(®) Inhub(®) is a dry powder inhaler approved as a generic equivalent to Advair(®) Diskus(®) (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD). This study aimed at confirming the local (lung) the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Dik, Kerwin, Edward M., White, Martha V., Miller, S. David, Haughie, Scott, Ward, Jonathan K., Allan, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133441/
https://www.ncbi.nlm.nih.gov/pubmed/31634023
http://dx.doi.org/10.1089/jamp.2019.1547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133441/
https://www.ncbi.nlm.nih.gov/pubmed/31634023
http://dx.doi.org/10.1089/jamp.2019.1547

Ejemplares similares